SAFC Invests In Commercial-Scale ADC Conjugation Manufacturing And Services

(RTTNews) - Sigma-Aldrich Corp. (SIAL) announced Monday that its custom manufacturing services business unit, SAFC Commercial, is expanding two of its manufacturing facilities in the United States to support drug manufacturers in efficiently bringing new targeted and cytotoxic therapies to market.

The company said that, as a direct result of increasing customer demand, SAFC is investing in commercial-scale manufacturing capacity for antibody drug conjugates or ADCs in St. Louis, MO, and expanding its high-potency active pharmaceutical ingredient or HPAPI manufacturing and storage at the Verona facility near Madison, WI.

The company stated that ADC expansion at the St. Louis site is expected to be completed by mid-2015. The updated facility will feature segregated areas for high-potent solids handling, manufacturing and aseptic bulk filling of product. Batches up to 600L/3kg can be manufactured under ISO 7 classification and the facility is suitable for HPAPI containment for SafeBridge™ Category 4 compounds.

Additional commercial-scale manufacturing capacity has also been designed to seamlessly accommodate future growth in demand for ADC production.